Caroline Dorsa - 14 Jun 2022 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
16 Jun 2022, 18:26:44 UTC
Prior SEC filing
27 May 2022
Next SEC filing
17 Jun 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/James Basta, Attorney-In-Fact

Key filing fact

Caroline Dorsa filed Form 4 for Intellia Therapeutics, Inc. (NTLA) on 16 Jun 2022.

Key facts

  • This page summarizes Caroline Dorsa's Form 4 filing for Intellia Therapeutics, Inc. (NTLA).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 16 Jun 2022, 18:26.

Change

  • Previous filing in this sequence was filed on 27 May 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NTLA transaction

Common Stock

Award

Transaction value
$0
Shares
+5,197
Change %
+69%
Price
$0.000000
Shares after
12,701
Date
14 Jun 2022
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NTLA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+7,688
Change %
Price
$0.000000
Shares after
7,688
Date
14 Jun 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,688
Exercise price
$38.49
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

Footnote F2

This option was granted on June 14, 2022 with respect to 7,688 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .